Comparative Pharmacology
Head-to-head clinical analysis: AMOXAPINE versus SURMONTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXAPINE versus SURMONTIL.
AMOXAPINE vs SURMONTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin, with anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day
50-75 mg/day orally in divided doses, increase gradually to 150-300 mg/day. Maximum 300 mg/day. Single bedtime dose may be used for maintenance (50-150 mg).
None Documented
None Documented
Parent drug: 8-12 hours; active metabolite (8-hydroxyamoxapine): approximately 30 hours; steady-state achieved in 3-5 days
Clinical Note
moderateAmoxapine + Budesonide
"The therapeutic efficacy of Budesonide can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone furoate
"The therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Fluticasone propionate."
Clinical Note
moderate11-27 hours (mean approximately 20 hours) for the parent drug; the active metabolite desmethyltrimipramine has a half-life of 15-30 hours. Steady-state is achieved within 5-7 days.
Primarily renal (approximately 60-70% as metabolites, <5% unchanged); minimal fecal elimination (<10%)
Renal excretion of metabolites accounts for approximately 70-80% of elimination, with about 20-30% excreted in feces via biliary elimination. Unchanged drug in urine is less than 5%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
Amoxapine + Desmopressin
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin."